482 - Efficacy and safety of sequential topical 0.1% mometasone furoate cream and 2% crisaborole in the treatment of mild to moderate atopic dermatitis in children aged over 2 years—a multicentre parallel randomised controlled study in China

Abstract

Abstract Background Atopic dermatitis (AD) is a chronic, recurrent pruritic, inflammatory skin disease associated with genetic allergies. Crisaborole is a phosphodiesterase 4 (PDE4) inhibitor approved by the US Food and Drug Administration for the treatment of patients over 2 years of age with mild to moderate AD. Previous studies have focused on the efficacy of crisaborole in the treatment of AD, and its influence on AD recurrence is not clear. Objective To explore the efficacy and safety of sequential topical 0.1% mometasone furoate cream (Elosone) and crisaborole in the treatment of mild to moderate AD in children, and to investigate the effect of crisaborole on the recurrence of AD. Methods Results Conclusion Treatment of mild to moderate AD in children over 2 years of age with sequential topical 0.1% mometasone furoate and crisaborole significantly reduced relapses and the amount of mometasone furoate prescribed and was safe and well tolerated by patients.